deaths (OS)

Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)

versus placebo
nivolumab alone vs. placebo 1 certainty unassessable-15%
nivolumab plus ipilimumab vs. placebo 1 certainty unassessable-7%

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus etoposide plus platin
durvalumab plus etoposide and platin vs. etoposide plus platin 1 certainty unassessablestatistically conclusive-25%
durvalumab plus tremelimumab plus SoC vs. etoposide plus platin 1 certainty unassessable-17%
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-28%
ipilimumab plus SoC vs. placebo plus SoC 1 certainty unassessable-6%
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-18%